{"filing":{"accession_number":"0001193125-26-276766","cik":"0001121404","ticker":"SNYNF","company_name":"Sanofi","form":"6-K","filing_date":"2026-06-22","report_date":null,"primary_document":"d104835d6k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1121404/000119312526276766/d104835d6k.htm"},"events":[{"id":12637,"run_id":11210,"accession_number":"0001193125-26-276766","anchor_item_number":"EX-99.1","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"summary":"This press release announces FDA accelerated approval of Tzield (teplizumab-mzwv) for a new indication—delaying decline in endogenous insulin production in children aged 8–17 with recently diagnosed stage 3 type 1 diabetes. The approval is a significant regulatory and commercial milestone for Sanofi's pipeline, expanding the drug's approved indications and market opportunity. While not a discrete M\u0026A, debt, or capital event, the regulatory approval of a first-in-class disease-modifying therapy for a new patient population is a material operational and strategic development that would affect a reasonable investor's assessment of the company's product portfolio and revenue prospects.","company_name":"Sanofi","ticker":"SNYNF","filing_date":"2026-06-22","form":"6-K","submitted_at":null,"items":[{"id":9544,"accession_number":"0001193125-26-276766","item_number":"EX-99.1","item_title":"d104835dex991.htm","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"This press release announces FDA accelerated approval of Tzield (teplizumab-mzwv) for a new indication—delaying decline in endogenous insulin production in children aged 8–17 with recently diagnosed stage 3 type 1 diabetes. The approval is a significant regulatory and commercial milestone for Sanofi's pipeline, expanding the drug's approved indications and market opportunity. While not a discrete M\u0026A, debt, or capital event, the regulatory approval of a first-in-class disease-modifying therapy for a new patient population is a material operational and strategic development that would affect a reasonable investor's assessment of the company's product portfolio and revenue prospects.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-06-22T15:29:07.619024+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":9544,"accession_number":"0001193125-26-276766","item_number":"EX-99.1","item_title":"d104835dex991.htm","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"This press release announces FDA accelerated approval of Tzield (teplizumab-mzwv) for a new indication—delaying decline in endogenous insulin production in children aged 8–17 with recently diagnosed stage 3 type 1 diabetes. The approval is a significant regulatory and commercial milestone for Sanofi's pipeline, expanding the drug's approved indications and market opportunity. While not a discrete M\u0026A, debt, or capital event, the regulatory approval of a first-in-class disease-modifying therapy for a new patient population is a material operational and strategic development that would affect a reasonable investor's assessment of the company's product portfolio and revenue prospects.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-06-22T15:29:07.619024+00:00","company_name":"Sanofi","ticker":"SNYNF","filing_date":"2026-06-22"}]}